Headshot of Corey McMillan, PhD
July 19, 2022

Corey McMillan, PhD, is an associate professor of neurology at the University of Pennsylvania and principal investigator of the Penn Bioinformatics in Neurodegenerative Disease (BiND) Lab. He is also a member of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium. His research focuses on multimodal and bioinformatic approaches to improve our understanding of the biological basis of neurodegenerative conditions. Here, he shares his start in rare disease research, exciting discoveries, and future goals.

Andrea and her daughter, Bianca, celebrating World CDG Awareness Day
July 07, 2022

Andrea Miller, JD, MHA, is the founder and president of CDG CARE (Community Alliance and Resource Exchange), a patient advocacy group that supports individuals and families affected by congenital disorders of glycosylation (CDG). CDG is a large group of rare, inherited disorders that affect a complex process in the body called glycosylation. Here, she shares her journey to rare disease advocacy, impactful work by CDG CARE, and collaboration with the Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC).

Rare Diseases Clinical Research Network logo with text: Research Roundup, #RDCRN
July 06, 2022

Each month, we share summaries of recent Rare Diseases Clinical Research Network (RDCRN) grant-funded publications. Catch up on the latest RDCRN research.

The Franklin family at a playground, and Dee List wearing a graduation cap
June 30, 2022

Congenital disorders of glycosylation (CDG) are a large group of rare, inherited disorders that affect a complex process in the body called glycosylation. Most children who are diagnosed with CDG have neurological issues and symptoms, developmental problems, growth delays, and problems with organs not working like they should. PMM2-congenital disorder of glycosylation (PMM2-CDG) is the most common type of CDG. Here, we speak to two parents of children diagnosed with PMM2-CDG—Heather Franklin (mother of Michaela, age 13, and Nathaniel, age 11) and Bobbie List (mother of Danielle “Dee,” age 21)—about their journey as a caregiver and advocate for children with a rare disease. 

CEGIR members gathering in 2020
June 27, 2022

For the first time, patients diagnosed with eosinophilic esophagitis (EoE) have a treatment option approved by the US Food and Drug Administration (FDA). Years of clinical trials led to the official approval of Dupixent (dupilumab) on May 20, 2022. To begin these clinical trials, researchers first had to answer a question—how do we evaluate the effectiveness of a treatment for EoE? A collaborative team of patients, advocates, researchers, and clinicians from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) worked to identify outcome metrics to make these clinical trials possible. 

Kent Lai, PhD, sitting in a chair in his lab
June 21, 2022

Kent Lai, PhD, is a professor in the Division of Medical Genetics (Pediatrics) at the University of Utah. He is also a member of the Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC). His research focuses on the development of novel therapeutics for both common and rare diseases, including congenital disorders of glycosylation (CDG). Here, he shares his start in rare disease research, exciting discoveries, and future goals. 

Headshot of Steven Sloan, MD, PhD
June 14, 2022

Steven Sloan, MD, PhD, is an assistant professor in the Department of Human Genetics at the Emory University School of Medicine, as well as a member of the Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC). His research focuses on glial development and the role these cells play in neurodevelopmental and neuropsychiatric diseases, including congenital disorders of glycosylation (CDG). Here, he shares his start in rare disease research, exciting discoveries, and future goals.